Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537715 · ClinicalTrials.gov registry record · Phase 1
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
A Phase 1 study, sponsored by Epizyme.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04537715 is a Phase 1 study that has completed, run by Epizyme. The registered enrollment target is 42 participants.
The verdict
NCT04537715, a Phase 1 study, has completed, sponsored by Epizyme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The participants of this study will have advanced malignancies (also known as advanced cancer). The main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the tazemtostat (the study drug) when administered in combination with another drug. Part 1 of the study will evaluate the interaction between the drugs tazemetostat and itraconazole. Part 2 of the study will evaluate the interaction between the drugs tazemetostat and rifampin For both Parts 1 and 2, safety and the level that effects of the study drug can be tolerated (known as tolerability) will be assessed throughout.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG Tazemetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-04-23 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04537715
The ClinicalTrials.gov registry entry for NCT04537715 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epizyme, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT04537715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04537715 about?
NCT04537715 is a clinical study titled "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels". The participants of this study will have advanced malignancies (also known as advanced cancer). The main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the tazemtostat (the study drug) when administered in combination with another drug. Part 1 of the study will e...
What is the current status of trial NCT04537715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-04-23. Estimated completion is 2023-04-03.
What interventions are being tested in trial NCT04537715?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT04537715?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.